Sutro Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by Sutro Biopharma, Inc. on June 3, 2021. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Market under the symbol STRO.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
The primary material event reported is the outcome of the stockholder vote at the Annual Meeting. No financial material changes versus prior periods are disclosed in this document.
Management Commentary and Governance Outcomes
Two proposals were adopted by the stockholders:
- Election of Directors: Three Class III directors were elected to serve three-year terms expiring at the 2024 Annual Meeting. The voting results were as follows:
| Nominee | Shares For | Shares Withheld | Broker Non-Votes |
|---|---|---|---|
| Joseph Lobacki | 31,197,523 | 5,379,167 | 3,383,433 |
| Daniel Petree | 28,235,296 | 8,341,394 | 3,383,433 |
| Shalini Sharp | 30,808,790 | 5,767,900 | 3,383,433 |
- Ratification of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021. The vote was 39,869,917 shares for, 76,443 against, and 13,763 abstaining.
Key Facts for Investor Verification
- Verify the tenure and background of the newly elected Class III directors (Lobacki, Petree, Sharp).
- Confirm the engagement terms with Ernst & Young LLP for the 2021 fiscal year.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial health metrics.